Metformin as RenoProtector of Progressive Kidney Disease

NCT ID: NCT03831464

Last Updated: 2023-12-19

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 290 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-05
• Study Completion Date: 2024-12-31

Brief Summary

A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication (renoprotection ) in a new class of patients (chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant for more than 3 years).

Detailed Description

The intervention consists in the treatment of patients with progressive kidney disease and blindly randomized to the treatment group with metformin as medication, added to their usual treatment. Metformin is a well-known and cheap medication used for many years and still used as main treatment of type 2 diabetes. In our study, this 'old' product will be used for a 'new' indication, slowing down the progression of CKD. After randomization in the participating renal care clinic, patients in the intervention group will be treated with metformin at a dose of 1000 mg/day (2x500mg) in the evening during 30 months (Metformin - Glucophage SR (Merck KGaA)). During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment At each visit during the study period, the metformin medication will be hand over to the patient in a HDPE bottle, closed with a MEMS cap (Medication Event Monitoring System). The MEMS a cap that registers the time and date of each opening (presumed intake of the medication in the bottle).

Patients blindly randomized to the control group will receive placebo treatment (2 tablets per day) also in a MEMS device and will continue to receive usual care. Control patients will have the same data collection.

Follow-up of patients during the entire study period will be the responsibility of the treating nephrologist in the renal care clinic. All patients will have a baseline data collection at study entry (demographics, comorbidities, concomitant medication, clinical parameters, lab results). During the study period of 30 months patients will have follow-up visits at their renal care clinic every four months with collection of follow-up data (concomitant medication, clinical parameters, routine lab results and drug related problems). Extra blood and urine samples will be collected for a centralized second determination of serum creatinine and proteinuria.

Conditions

Chronic Kidney Diseases

Keywords

CKD; Metformin; Renoprotector

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Metformin treatment group

Group Type: EXPERIMENTAL

Metformin Hydrochloride

Intervention Type: DRUG

The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.

During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment .

Placebo control group

Group Type: PLACEBO_COMPARATOR

Placebo Oral Tablet

Intervention Type: DRUG

The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.

Interventions

Metformin Hydrochloride

The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.

During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment .

Intervention Type: DRUG

Placebo Oral Tablet

The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adult patients (≥18 years) of both gender
• Seen on a regular base in one of the participating outpatient clinics of renal care with a previous consultation within the last year
• Having a chronic kidney disease (including having a transplant kidney for more than 3 years) with:

• a CKD stage 2, 3A or 3B (i.e. with estimated glomerular filtration rate (eGFR) between 30 and 70 ml/min/1.73m2) at the time of the baseline visit
• showing a decline of eGFR between 3.0 and 20.0 ml/min/year determined using at least three determinations of eGFR (CKD-Epi formula) whereby the oldest one should be from more than 1 year ago and the most recent will be the one of the baseline visit. For transplant patients the decline will be based on serum creatinine values determined during the preceding 24 months. For all other patients, the decline will be based on values determined within the last five years

Exclusion Criteria

1. Illiteracy: patients not knowing how to read or write

2. Patients not able to communicate in Dutch or French

3. Patients with mental deterioration, incapable to give informed consent and to understand the safety instructions of the study (at the discretion of the treating nephrologist)

4. Patients with one of the following clinical problems:

• Patients with nephrotic syndrome
• Patients showing a fast decline of renal function (more than 20 ml/min/year) during the preceding five years
• Diabetes mellitus (any type: 1, 2, Maturity Onset Diabetes of the Young (MODY), New Onset Diabetes After Transplantation (NODAT)) confirmed by a glycemia level >125 mg/dl (7.0 mmol/L) after a fasting time of 8 hours
• Patients with a renal transplantation for less than 3 years
• Patients with multi-organ transplantation
• History of other solid organ transplantations
• Chronic obstructive pulmonary disease (COPD) stage Gold IV (Oxygene-dependency)
• Congestive heart failure (NYHA stage IV)
• Inflammatory bowel disease (IBD)
• Stoma
• Hepatic insufficiency or cirrhosis, acute alcohol intoxication or alcoholism (> 20 glasses of alcoholic beverages per week)
• History of metabolic diseases (e.g. mitochondrial encephalomyopathy (MELAS), lactic acidosis, stroke-like episodes, etc…)
• Pregnancy and/or lactating women at the time of recruitment and during the study period
• Patient with prior use of metformin within the past 12 months (e.g. glucose intolerance, polycystic ovary syndrome, etc…) or with other study medication taken within the framework of another clinical trial

5. Patients showing elevated blood lactate level(s) at the time of recruitment (i.e. a confirmed lactate level ≥ 2.5 mmol/L at baseline and a confirmed lactate level ≥ 2.5 mmol/L after 4 weeks (±1 week)).

6. Patients showing a confirmed (after 3 months) serum bicarbonate level < 22 mmol/L (or < 20 mmol/L if delay of more than 1 hour between sampling and determination)

7. Hypersensitivity to metformin or to any of the excipients listed in section 6.1 of the Glucophage SR SmPC (see Attachment A5 Glucophage SR SmPC)

8. One of the following diseases during the previous 6 months: myocardial infarction, shock, acute problems of decompensated heart failure or respiratory failure.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Antwerp

OTHER

Sponsor Role: collaborator

Universiteit Antwerpen

OTHER

Sponsor Role: lead

Responsible Party

Prof Dr. Marc De Broe

Prof Dr.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

AZ Delta

Roeselare, West-Vlaanderen, Belgium

OLVZ Aalst

Aalst, , Belgium

Epicura Ath

Ath, , Belgium

Epicura Baudour

Baudour, , Belgium

Imelda Ziekenhuis Bonheiden

Bonheiden, , Belgium

CHU Brugmann

Brussels, , Belgium

Hôpital Erasme

Brussels, , Belgium

UZ Brussel

Brussels, , Belgium

Grand Hôpital de Charleroi

Charleroi, , Belgium

Antwerp University Hospital

Edegem, , Belgium

Ghent University Hospital

Ghent, , Belgium

Jessa Ziekenhuis

Hasselt, , Belgium

Centre Hospitalier Régional de la Citadelle

Liège, , Belgium

Centre Hospitalier Universitaire Liège (CHU Liège)

Liège, , Belgium

Centre Hospitalier Régional de Namur

Namur, , Belgium

AZ Nikolaas

Sint-Niklaas, , Belgium

Centre Hospitalier de Wallonie Picarde

Tournai, , Belgium

AZ Turnhout

Turnhout, , Belgium

CHR Verviers

Verviers, , Belgium

Countries

Belgium

References

El-Damanawi R, Stanley IK, Staatz C, Pascoe EM, Craig JC, Johnson DW, Mallett AJ, Hawley CM, Milanzi E, Hiemstra TF, Viecelli AK. Metformin for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013414. doi: 10.1002/14651858.CD013414.pub2.

Reference Type: DERIVED

PMID: 38837240 (View on PubMed)

Other Identifiers

RenoMet

Identifier Type: -

Identifier Source: org_study_id